Pages that link to "Q116792872"
Jump to navigation
Jump to search
The following pages link to Marzena Wełnicka-Jaśkiewicz (Q116792872):
Displaying 25 items.
- Mesenchymal phenotype of CTC-enriched blood fraction and lymph node metastasis formation potential. (Q31158116) (← links)
- Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized p (Q33365185) (← links)
- Prognostic significance of ESR1 amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 polymorphisms in breast cancer patients (Q34951367) (← links)
- Epithelial-mesenchymal transition markers in lymph node metastases and primary breast tumors - relation to dissemination and proliferation (Q34978807) (← links)
- The risks and benefits of hormonal replacement therapy in healthy women and in breast cancer survivors (Q35217988) (← links)
- Radiotherapy for breast cancer in patients undergoing breast reconstruction or augmentation (Q38637575) (← links)
- Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancer (Q36349584) (← links)
- Stromal expression of ALDH1 in human breast carcinomas indicates reduced tumor progression. (Q36413616) (← links)
- Expression of epithelial to mesenchymal transition-related markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer. (Q36471883) (← links)
- Heterogeneity of mesenchymal markers expression-molecular profiles of cancer cells disseminated by lymphatic and hematogenous routes in breast cancer (Q37420863) (← links)
- Clinical evaluation of developed PCR-based method with hydrolysis probes for TOP2A copy number evaluation in breast cancer samples. (Q38344300) (← links)
- Modified direct-double-differential PCR for gene dosage quantification of HER2. (Q40438795) (← links)
- CD99 correlates with low cyclin D1, high topoisomerase 2 status and triple negative molecular phenotype but is prognostically irrelevant in breast carcinoma. (Q41087757) (← links)
- Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study (Q45018097) (← links)
- Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial (Q46465645) (← links)
- Are bilateral breast cancers different from breast cancers coexisting with ovarian cancer? An immunohistochemical analysis aimed at intrinsic tumor phenotype (Q51020917) (← links)
- CD73 expression as a potential marker of good prognosis in breast carcinoma. (Q53270735) (← links)
- Prognostic value of TOP2A gene amplification and chromosome 17 polysomy in early breast cancer. (Q54318735) (← links)
- (CA)n microsatellite polymorphism of ERBB-1 in breast cancer. (Q54597501) (← links)
- Spectrum of Epithelial-Mesenchymal Transition Phenotypes in Circulating Tumour Cells from Early Breast Cancer Patients (Q61799015) (← links)
- Clinical and Biological Significance of Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer Patients (Q64249317) (← links)
- Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group (Q79393410) (← links)
- Gene copy numbers of HER family in breast cancer (Q80695489) (← links)
- Pattern of care in locally advanced breast cancer: focus on local therapy (Q85092881) (← links)
- Aggressive Phenotype of Cells Disseminated via Hematogenous and Lymphatic Route in Breast Cancer Patients (Q88373411) (← links)